Alyeska Investment Group’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-589,848
| Closed | -$15M | – | 636 |
|
|
2024
Q4 | $15M | Hold |
589,848
| – | – | 0.06% | 290 |
|
|
2024
Q3 | $16.7M | Sell |
589,848
-124,556
| -17% | -$3.52M | 0.09% | 254 |
|
|
2024
Q2 | $18.8M | Sell |
714,404
-437,367
| -38% | -$11.5M | 0.11% | 217 |
|
|
2024
Q1 | $35M | Buy |
1,151,771
+130,735
| +13% | +$3.97M | 0.22% | 154 |
|
|
2023
Q4 | $28.7M | Sell |
1,021,036
-207,209
| -17% | -$5.82M | 0.19% | 156 |
|
|
2023
Q3 | $33.3M | Sell |
1,228,245
-192,825
| -14% | -$5.23M | 0.23% | 153 |
|
|
2023
Q2 | $43.7M | Buy |
1,421,070
+782,676
| +123% | +$24.1M | 0.32% | 100 |
|
|
2023
Q1 | $23M | Buy |
638,394
+125,367
| +24% | +$4.52M | 0.2% | 142 |
|
|
2022
Q4 | $20.3M | Buy |
+513,027
| New | +$20.3M | 0.21% | 148 |
|
|
2022
Q3 | – | Sell |
-354,729
| Closed | -$14.9M | – | 465 |
|
|
2022
Q2 | $14.9M | Buy |
354,729
+281,335
| +383% | +$11.8M | 0.17% | 172 |
|
|
2022
Q1 | $2.86M | Buy |
+73,394
| New | +$2.86M | 0.03% | 379 |
|
|
2021
Q4 | – | Sell |
-125,000
| Closed | -$4.52M | – | 716 |
|
|
2021
Q3 | $4.52M | Sell |
125,000
-226,597
| -64% | -$8.19M | 0.06% | 348 |
|
|
2021
Q2 | $14.4M | Buy |
351,597
+25,000
| +8% | +$1.02M | 0.17% | 169 |
|
|
2021
Q1 | $14.2M | Sell |
326,597
-437,220
| -57% | -$19.1M | 0.18% | 152 |
|
|
2020
Q4 | $38.2M | Buy |
763,817
+260,082
| +52% | +$13M | 0.54% | 44 |
|
|
2020
Q3 | $21.2M | Buy |
503,735
+68,540
| +16% | +$2.88M | 0.32% | 95 |
|
|
2020
Q2 | $21.1M | Buy |
+435,195
| New | +$21.1M | 0.32% | 113 |
|